Wang T, et al. - Whether incretin-based therapies (IBTs) increase diabetic retinopathy (DR) risk compared with other antihyperglycemics was investigated in this analysis. For this investigation, the researchers implemented an active comparator, new-user cohort design using a nationwide 20% random sample of fee-for-service U.S. Two hundred thirteen thousand, six hundred fifty-two eligible patients were identified. The findings from the present study suggested that IBTs used for approximately 1 year did not increase the DR risk.